2,594
Views
5
CrossRef citations to date
0
Altmetric
Neurology

Predicting initiation of preventive migraine medications: exploratory study in a large U.S. medical claims database

, , , , , & show all
Pages 51-61 | Received 04 Feb 2019, Accepted 16 Aug 2019, Published online: 09 Sep 2019

References

  • Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache. 2018;58:496–505.
  • Buse DC, Loder EW, Gorman JA, et al. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013;53:1278–1299.
  • Lipton RB, Bigal ME, Diamond M, AMPP Advisory Group, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–349.
  • Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31:301–315.
  • GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16:877–897.
  • Korolainen MA, Kurki S, Lassenius MI, et al. Burden of migraine in Finland: health care resource use, sick-leaves and comorbidities in occupational health care. J Headache Pain. 2019;20:13.
  • Martelletti P, Schwedt TJ, Lanteri-Minet M, et al. My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 2018;19:115.
  • Carville S, Padhi S, Reason T, et al. Guideline Development Group. Diagnosis and management of headaches in young people and adults: summary of NICE guidance. BMJ. 2012;345:e5765.
  • Holland S, Silberstein SD, Freitag F, et al. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the quality standards subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1346–1353.
  • Pringsheim T, Davenport W, Mackie G, et al. Canadian Headache Society Prophylactic Guidelines Development Group. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39:S1–S59.
  • Silberstein SD, Holland S, Freitag F, et al. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337–1345. (Erratum in: Neurology. 2013;80:871.)
  • García-Azorin D, Santos-Lasaosa S, Gago-Veiga AB, et al. Real world preventative drug management of migraine among Spanish neurologists. J Headache Pain. 2019;20:19.
  • Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second International Burden of Migraine Study (IBMS-II). Headache. 2013;53:644–655.
  • Burch RC, Loder S, Loder E, et al. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache. 2015;55:21–34.
  • Buse DC, Pearlman SH, Reed ML, et al. Opioid use and dependence among persons with migraine: results of the AMPP study. Headache. 2012;52:18–36.
  • Ferrari A, Baraldi C, Sternieri E. Medication overuse and chronic migraine: a critical review according to clinical pharmacology. Expert Opin Drug Metab Toxicol. 2015;11:1127–1144.
  • Lipton RB, Buse DC, Serrano D, et al. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2013;53:1300–1311.
  • Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008;71:1821–1828.
  • Katsarava Z, Buse DC, Manack AN, et al. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16:86–92.
  • Torres-Ferrús M, Quintana M, Fernandez-Morales J, et al. When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month. Cephalalgia. 2017;37:104–113.
  • Abu Bakar N, Tanprawate S, Lambru G, et al. Quality of life in primary headache disorders: a review. Cephalalgia. 2016;36:67–91.
  • Lantéri-Minet M, Duru G, Mudge M, et al. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia. 2011;31:837–850.
  • Messali A, Sanderson JC, Blumenfeld AM, et al. Direct and indirect costs of chronic and episodic migraine in the United States: a web-based survey. Headache. 2016;56:306–322.
  • Shah AM, Bendtsen L, Zeeberg P, et al. Reduction of medication costs after detoxification for medication-overuse headache. Headache. 2013;53:665–672.
  • Wu J, Hughes MD, Hudson MF, et al. Antimigraine medication use and associated health care costs in employed patients. J Headache Pain. 2012;13:121–127.
  • Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn). 2015;21:973–989.
  • Bursac Z, Gauss CH, Williams DK, et al. Purposeful selection of variables in logistic regression. Source Code Bio Med. 2008;3:17.
  • Eross E, Dodick D, Eross M. The sinus, allergy and migraine study (SAMS). Headache. 2007;47:213–224.
  • Buse DC, Sollars CM, Steiner TJ, et al. Why hurt? A review of clinical instruments for headache management. Curr Pain Headache Rep. 2012;16:237–254.
  • Minen MT, Loder E, Tishler L, et al. Migraine diagnosis and treatment: a knowledge and needs assessment among primary care providers. Cephalalgia. 2016;36:358–370.
  • Gallagher RM, Alam R, Shah S, et al. Headache in medical education: medical schools, neurology and family practice residencies. Headache. 2005;45:866–873.
  • Dall TM, Storm MV, Chakrabarti R, et al. Supply and demand analysis of the current and future US neurology workforce. Neurology. 2013;81:470–478.
  • Mauser ED, Rosen NL. So many migraines, so few subspecialists: analysis of the geographic location of United Council for Neurologic Subspecialties (UCNS) certified headache subspecialists compared to United States headache demographics. Headache. 2014;54:1347–1357.
  • Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629–808.
  • Thorlund K, Sun-Edelstein C, Druyts E, et al. Risk of medication overuse headache across classes of treatments for acute migraine. J Headache Pain. 2016;17:107.
  • Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache. 2003;43:36–43.
  • Hepp Z, Dodick DW, Varon SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35:478–488.
  • Turner DP, Golding AN, Houle TT. Using a graphical risk tool to examine willingness to take migraine prophylactic medications. Pain. 2016;157:2226–2234.
  • Ford JH, Jackson J, Milligan G, et al. A real-world analysis of migraine: a cross-sectional study of disease burden and treatment patterns. Headache. 2017;57:1532–1544.
  • Shah N, Pike J, Mutebi A, et al. The use of migraine prophylaxis treatments in the United States of America: analysis of data from clinical practice [abstract]. American Headache Society 58th Annual Scientific Meeting, San Diego, CA; 2016 [cited 2017 June 6]. Available from: https://www.mdlinx.com/nursing/conference-abstract.cfm/58197/?nonus=0&searchstring=&coverage_day=&page=1.
  • Sarchielli P, Granella F, Prudenzano MP, et al. Italian guidelines for primary headaches: 2012 revised version. J Headache Pain. 2012;13:31–S70.
  • Flores NM, Lee LK, Gajria K, et al. Health related quality of life and health care resource use burden in migraine with and without nausea [abstract]. ISPOR 18th Annual European Congress, Milan; November 2015; [cited 2018 Aug 09]. Available from: https://www.valueinhealthjournal.com/article/S1098-3015(15)01581-8/fulltext
  • Raval AD, Shah A. National trends in direct health care expenditures among US adults with migraine: 2004 to 2013. J Pain. 2017;18:96–107.
  • Friedman BW, Serrano D, Reed M, et al. Use of the emergency department for severe headache. A population-based study. Headache. 2009;49:21–30.
  • Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015;55:103–122.
  • May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016;12:455–464.
  • Dumas P. What really happens when you go to the ER with migraine [newsletter]; September 28, 2015 [cited 2017 Sep 13]. Available from: https://migraineagain.com/what-really-happens-when-you-go-to-emergency-with-migraine
  • Bigal ME, Lipton RB. Overuse of acute migraine medications and migraine chronification. Curr Pain Headache Rep. 2009;13:301–307.
  • Cho SJ, Chu MK. Risk factors of chronic daily headache or chronic migraine. Curr Pain Headache Rep. 2015;19:465.
  • Jonsson P, Hedenrud T, Linde M. Epidemiology of medication overuse headache in the general Swedish population. Cephalalgia. 2011;31:1015–1022.
  • Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache. 2007;47:355–363.
  • Bonafede M, Sapra S, Tepper SJ, et al. Healthcare costs and utilization and medication treatment patterns among migraine patients: a retrospective analysis [abstract]. Headache. 2017;57:211. [PS58].
  • Kolodner K, Lipton RB, Lafata JE, et al. Pharmacy and medical claims data identified migraine sufferers with high specificity but modest sensitivity. J Clin Epidemiol. 2004;57:962–972.